0001213900-24-056879.txt : 20240628 0001213900-24-056879.hdr.sgml : 20240628 20240628084509 ACCESSION NUMBER: 0001213900-24-056879 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allarity Therapeutics, Inc. CENTRAL INDEX KEY: 0001860657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41160 FILM NUMBER: 241081580 BUSINESS ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 401-426-4664 MAIL ADDRESS: STREET 1: 24 SCHOOL ST., 2ND FLOOR CITY: BOSTON STATE: MA ZIP: 02108 8-K 1 ea0208659-8k_allarity.htm CURRENT REPORT
false 0001860657 0001860657 2024-06-27 2024-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2024

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41160   87-2147982
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

24 School Street, 2nd Floor,
Boston, MA		   02108
(Address of principal executive offices)   (Zip Code)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 27, 2024, Allarity Therapeutics, Inc. (the “Company”), issued a press release announcing that the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was granted a hearing before a Nasdaq hearings panel.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated June 27, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
   
  By: /s/ Thomas H. Jensen
    Thomas H. Jensen
    Chief Executive Officer
     
Dated: June 28, 2024    

 

 

 

2

 

 

 EX-99.1 2 ea020865901ex99-1_allarity.htm PRESS RELEASE, DATED JUNE 27, 2024

Exhibit 99.1

 

 

 

Allarity Granted Hearing Before Nasdaq Panel to Present Plan
of Regaining Compliance

 

Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market (“NASDAQ”) that it was granted a hearing before a Nasdaq Hearings Panel (the “Panel”).

 

This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq’s notification, disclosed in Allarity’s Form 8-K filed with the SEC on June 21, 2024, of Allarity’s non-compliance with Nasdaq Listing Rule 5550(a)(2), also known as the Bid-Price Rule. This rule requires that a company’s stock maintain a minimum bid price of $1.00 per share for at least 30 consecutive business days.

 

As previously disclosed in Allarity’s preliminary proxy statement filed with the SEC on June 21, 2024, Allarity intended to appeal the determination, and the Company’s request for hearing was formally submitted on June 25, 2024.

 

Allarity now intends to proceed through the hearings appeal process with Nasdaq.

 

The Company has already started preparing diligently for the hearing, with a preparation schedule in place to ensure thorough readiness.

 

The Company plans to issue an update on the Nasdaq hearings process as soon as substantive updates are available.

 

 

Allarity Therapeutics, Inc.    I    24 School Street, 2nd Floor    I    Boston, MA    I    U.S.A.    I    NASDAQ:    ALLR    I    www.allarity.com

 

Page 1 of 2

 

 

 

 

About Allarity Therapeutics

 

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

 

Follow Allarity on Social Media

 

LinkedIn: https://www.linkedin.com/company/allaritytx/

X: https://twitter.com/allaritytx

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the risks associated with maintaining compliance with Nasdaq’s continued listing requirements, the potential outcomes of the Nasdaq hearings appeal process, the Company’s ability to present a successful plan for regaining compliance, and other risks inherent in Allarity’s business. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with maintaining compliance with Nasdaq’s continued listing requirements, the potential outcomes of the Nasdaq hearings appeal process, the trading price of Allarity’s shares of common stock may be volatile, the risk that the Company may not be able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for stenoparib or any of our other therapeutic candidates and companion diagnostics or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, and the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement filed on April 17, 2024, and our Form 10-K annual report on file with the Securities and Exchange Commission (the “SEC”), available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

 

###

Company Contact:

investorrelations@allarity.com

 

Media Contact:

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

 

 

Allarity Therapeutics, Inc.    I    24 School Street, 2nd Floor    I    Boston, MA    I    U.S.A.    I    NASDAQ:    ALLR    I    www.allarity.com

 

Page 2 of 2

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 allr-20240627.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 allr-20240627_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 allr-20240627_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 27, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 27, 2024
Entity File Number 001-41160
Entity Registrant Name ALLARITY THERAPEUTICS, INC.
Entity Central Index Key 0001860657
Entity Tax Identification Number 87-2147982
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 24 School Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02108
City Area Code 401
Local Phone Number 426-4664
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ALLR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://allaritytherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports allr-20240627.xsd allr-20240627_lab.xml allr-20240627_pre.xml ea0208659-8k_allarity.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0208659-8k_allarity.htm": { "nsprefix": "ALLR", "nsuri": "http://allaritytherapeutics.com/20240627", "dts": { "schema": { "local": [ "allr-20240627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "allr-20240627_lab.xml" ] }, "presentationLink": { "local": [ "allr-20240627_pre.xml" ] }, "inline": { "local": [ "ea0208659-8k_allarity.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://allaritytherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0208659-8k_allarity.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0208659-8k_allarity.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://allaritytherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-056879-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-056879-xbrl.zip M4$L#!!0 ( *1%W%CGL6$R,@, <, 1 86QL],_T'U:\<7H"2%0#*$3E(FY ;-[:DC;!E49,F1Y #]^DJ^ M<3$0H*V?Y-4Y9W>UN[(;9]. @#?$!6:T:90LQP"(NLS#=-@T'OIFJ]_N= QP M=OKQ U!/XY-I@@N,B%<'WYAK=JC/3L -#% =7"**.)2,GX!'2")M81>8( [: M+ @)DDAM))[JH&J5RRXPS1UT'Q'U&'_H=7+=D92AJ-OV9#*Q*'N#$\;'PG)9 ML)M@7T(9B5S-F3KILQO]&@LW)W^^&E?%\;2'GT<1_1K=#+Z[X@E&=VUX)W^' MM>K3"SF/+HGC/XZ/*C-'XN#UUWG_M=VZ?;ELW=]?)2X;PAVA )5#"J:ALXO M36]2L1@?VF7'*=G/U]U^C#,28'U*,!VO@Y=JM9H=[V;0 G(ZX"23KMAZ>P % MRI75+MZ"QU1(2-TEO"=SPB*X:B>;2U"\%GJ40'$&]= *3B#7&K(W6VTH?/E+ M!HR$.80PS,$^%(-8--U8 @LNBT!E7 69(TBPCY%G GY$$G=<"*$ M+MI#.>M@2"E3C:ZF+;5H6QABUN<$?1#I03T0DW:^^XTT&XS=7,8 M 'M-(UDN"&?2'O(QQ7$8Z925@*EG*M+IJV7,;-BKX*)2))!W2T_C='6KAM+-AZR$?Q$-:U^W4- 36UZ21VD8< M^4U#%8";66U_JK0MU6X91'O8,J1QC59/*G6<24#N%E0*EX@282'B$JN>7[@I MDM"QU/2[!3= ^Q$&L/]AY@0.]LU<41#YCREWM7XQUX:]/&7J?742&RI=QB6@ MA?'>=M,FWX@N,W\5!3>"RB$H^VZ<1%BG9RV'5F/\?[%:(#)\40?\R'.KV@"XH M.E_7 @T[45/+/U!+ P04 " "D1=Q85X5=[/X* " A@ %0 &%L;'(M M,C R-# V,C=?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XXFS+9#L9!<93[(P M-INDL6>V[:)8T!+C"*')@)(3^]^7E$19HG@D)45)SL6,1WP/]5)\3%)?QY]^ MW&TH>B$B33@['QT??1PAPB(>)VQ]/OJZ&%\L9O/Y"*499C&FG)'S$>.C'W_X MXQ^0_//I3^,QNDH(C<_0%QZ-Y^R!?X]N\(::8D([*@V/$9^MO1=!JA\7A O=\(B[GX>C^OZGW,LN?T;#)Y?7T]8OP% MOW+QE!Y%?#.LPD6&LVU:U?9Q]['\4X1_H@E[.E-_K7!*D#Q>+#W;IGD[R4BUM*782SO-M[=X- A?K?6,O&:M/X>#H^.3[: MI?%('_S\" I.R3UY0'DSS[+]LT0I310)HW+;HR /=C-4B(F*GS"RQAF)U8Y. MU8Z._ZYV].=R\S5>$3I"2BGY -MUVJBK#)JX-GM'1,+C2_8^UV:T)_ORNR.R M_Z$!]7CG35CR#--WF:]'.K=]0]YWQ ]Q[H^T'.?)^XYT+?+_8CMK6W[SX;4? M5ZHV7LM/#8MDE\D)C,3:I*JB8P3.]Y!/#&7=5>T\:M1+U6C.1;OM:F;,ZTQ) M=+3F+Y.8)++NZ7?JPUA]R)LM__/[C,N5P,4JS02.,EU3WHSSD:5\8EI2R@NA M?6$1]32N5$PB+J>FYVQ,B\-8A#\(OK'NMFPUMQ3^3E=5?'%8Y"X HPV9("G? MBHB\J5?J;J&C5#K:4*E02RK"QE\7HQ]R#?I-J_[S:7*HQ4%'RR70=D-8MI0U M6EK0+';5S393NI?K94%TLL60V<=:@I3&<0=?R!W':N=7%*\M]HUR5UULM:7[ MN%$81"?;')F]7&F0$OGJYB\DC43RK);S7>UHR)QWNL5DJ^]KFK 0:!N#2:AI M/0WL]V2=J*E%65#GMT1M[!C& +WKH;_3MCD76,5!0#/$(3A;U(-0%>6)HPO& MMIC>DVD&8+9UZF'H@N($, >?DE1Z MOZ0L'@FEZGX 9OT#BDWLFA;8L,E+6QD4,: ]D)D\ I4AX6!S^:)6YW*9-+"Q M-;U/>%JVN_BIQ,$B9#H<2%$>AE2<)Y)JMR%Z&&HI7=,#6#6Y,61!$6/W!K)2 MR%&N]P_))8L'(5+I_ !BV+3C48H"A*/IK \-J?8)QE621I@67J[DMK2C>1:M M:T! NR8D+6%0H$#N0%B* ,U,'N(5F'\1+(;A4E/Z@:5EU8Y*)0L0%--;'R9* M[P62V5:(AFMXQH&ESF[*]IBM[L\"NB! Z3'7NFM;R!N@>)J!+EF69'OU/-W- M=K,BPM*XML05&Y YS819'@0+@"F3@4*&E X50B\]K^\2L$P]Q @VQY2Y)S6,):O*0%,^#]U "ZMW"TF.[R0P@#@B=;H< 03((-:-\@C1G$1?/O/:X MPXQOY0"XG_$87J'T1+F%:E 3FFAUA@0$V!"? &:-T _%,RF(J_=X\@J0JL$+ M<1=Q+ ]46OYSG3!R#+;?JG5+5X?=)E,684 DP>X ?DKE!_T!J1ATRT*!9OJ& MID[]0S,="LTT:&BF[X%F^;D#4T]\0_-R5!H3H*&YN1=T,B.]SK6S.3' M6['DK[:'LT&E%V3:5JW '&3AX=+RU@>+"E#K&17B$Y-\874K[@1_25@$+YDA MN1=@ --6:@QM>.C8#?;Q4RV(=9S7L:98E/=^2;3,SRC3-&D?8@I->) TC?4. M+H7:)Q)W/,TP_7?RW'DB;A=[P<-JV I)0QD>*C9[?< 4,4@&^3BQ+G%5-S2L MKY(9Y>Y> ;;8.KP"7"L, @*;H_8KP,75DT+DNIL5HX)@8$1H%COK9(NIJH]K M96%T<=M0JX?S[[74^/@BJ^PN].Z1,_@!@;;$54]#YG1OF^5!]#A@RNSU7(9R MG:>K\2K#1&H?OFMESF9VTTXUD>N"('K7=-.:IG6YX][\5229W/.,;S9;5M[E ML3TW".A<]7*G3=WC5E$0O=_ES"2AU**FV#$6"TZ3*,D2MOY%GGR*!-M:91.Y M @(VJ&EH*X) ;1E *FE#Q$GR&0O M5$6@3[86)-K*^7%_/%TMDXS:3B[;$F=S$F"NFI&,\B#8 $R9+.1EB#^@X^E? M5G]%.LIQ]]_PI< J>>QBOUEQ"F2?LJI<0=!A47-@D02! NS+I.&&HU**"JV/ M[%0-LY;F&.6N +#:TEW?* RBTVV.6E_^1E][&O(O=]&C-$6 %Q+L,M=#O\VD M.?S7-4$@T&&L=5)22I'6^G@AX3!EK?L7 6MOBX!USR)@'>(B8#UT$;#VM@C0 MNRU2A,AQZ79%DS4&DA-VJEU#T6'9Y,,B#0H5V!\X9E0AZ!#C.J-EGN),I><7 MFWS_5_*#I96 SEE.RRZ;55)+FR@(1KJ\.@0V$Y(Y?U^XT;;RU;=4&Q$RG0>@=[C+GQV%M7$1Y>L4R(^KW(I(7\@5G MN/0&MA>2NWZILLNT^3:E31L00IT&P?6%AL,*6?MVG"2 I/1(;*+0M6BTT6&I* M6+#Y EC(I4AKO;!PN2%B+:>WGP1_S1[+_*Q@VP"U6S8Z+3<9L4H#8J7+'\", M#D%%C$ZIZP>>W2&A>)%E$6ZI1>H8&]"LP4Q+%Q(PD+D6+91$ZGK+#<_0DJ.O M*4'9(T&7Y<_0U3/!%_7X^J61*%(O1!2KD0WXMD-_B"N"AIK7'/7I@Z!IH$F3J3RL M>7*=!R(5Z3.;43VY/;S$:X@D2SO( B(@+8K*$5>+D2YTDO_?\;L26R?LVA_)WA$B'K* M*JU&J[[K;P.CW3+SIB8U:1H4&A!G;_$+$'BH M7J^%";L7Q>S%,/C:ML;CQZ M6CQB>0!OMUFJ9E!I#+X*WAGD^/;"@ 88-QDZ(@)";X!-Z(9#'HGRT ^H"$:U M:$_G9^DA"R")/^_OR0,1ZKV#)=EEG^6.GCK., ;$NCY[&]P<\V2N-S ("-_J M%CK52U&] K12SXB55:#?5"4HK\7V^^7U3=?RD]RL-\F_5C@E,E\' #M5P %0 &%L;'(M,C R-# V,C=?<')E+GAM M;,V<37/;-A"&[YWI?V#5LRQ+SD?MV,W8BI71Q(E=RTG:7C(0"4D8@X & "WI MWQ<@144?!+CN@6L?;)E: /L^"X)< N#Y^V7*HR>J-)/BHM4].FY%5,0R86)Z MT?HZ:E^.^L-A*]*&B(1P*>A%2\C6^S]__26R/^>_M=O1@%&>G$4?9-P>BHE\ M%WTA*3V+/E)!%3%2O8N^$9ZY(W+ .%517Z9S3@VU7Q0-GT6OCWJ].&JW ?5^ MHR*1ZNO]<%/OS)BY/NMT%HO%D9!/9"'5HSZ*90JK<&2(R?2FMN/E\?JG*'[. MF7@\<[_&1-/(\A+Z;*G91D\GD?MKH[=IE7!.%#,K,[/= M94XSP^(\>!UGV.E+VSFMUWD5,T4G%RU;0-F6>J^.W_3>NG9^WS$RJ[GMI)JY M/M:*.CL^S!755)A<]HT]L%.$+HWM6C0I*W+M_Q\O#3.NX+H3=:.VZW%9:MNU M'PO+M5.E6US&.YYP%QFY)[OLY3E_3>.CJ7SJ))1U' KW(6>2\[#__,@;NAQK MHTALRIHX&5.>U__#VNR9=!KPJB3Q8&NL=FK78M^G[0!>JCB2*J'*LB[K(BK> M"=MAAUU;=.9$V8K:\8SQ3<0G2J8^.FL2TN/H-BC;1#,T+VW[B?-AP,FT&N>> M"9!G%P-HI1HLHA^HCA6;.RXU8'8L#T*D7@_*"(T#0B(1_-*."OG]SUW5Y:X.RWB@#Q__%2\!^H18K '55,)O:2K@#L#XR!U$\Q MJ7L4HO*^%@F4]L84G/_@P]Z3AX1ZP'1,>.'1P![38=P5YE#D*#EGK4Q4[/]0 MHL#0MXRAR%'2T!J)#0/O9TKM.!,<5?S64.0H"6B=R(:97PO#S,K-!7S)TO'/ M!Z>[K ^MH(Q1DDZ?*!2VY9,&8=P41XCOOB64,4JN&1*'PKEO]2C"AR*ART]T M%0)]8 HEC9)C!N6AH+Y3+"5J-6)Q_:!Q: N%C9)9A@6BT'X@RV%B5;$)*R8) MZZ%[BT#9HZ25(+DH(1B*6*JYW'I9/1]7?9D$A_2:@M!PH.2;SY".$I3+ M)+&X]/K/#1.T&PI%I3EXC@@O &9+P1[[WG8>W#L*'EHK=A/X-A1 M(2I&>#7G*CLH9)1DSR^L8<)WBKI(4WO; MG:_C4>; "LH:)>7SB6J8[1?YH(C;PS=:I6/)_=M#*@VAA%$2O("T MAB'O^%&-=\\$"A8ELZN4@S0F7"_C&1%3ZE^]4&T)!8R2Z87$H8V]4]#8.WWF MV(N2\?E$(;$MUH;;,^IVS-F4^'>2!0N ]]E@$@](;7K_7K[EQ^WN5FGNQ\!^ MJ,;N,84"Q]DB&9+7-.HL888FA4L#)HB(;4JUV=?FR<[K2T$#@+.'$B@:Y?'^ M=\KY)R$78D2)EH(FQ:U^Z F_MP@T"HASB#5R44+P3?+,4E+Y0E#E.0<\IE#D MB'.''GDX:R^+16/.*$8%HNV?E[U[85G*L-SYGN&4-J(2V$KI:% 'J6$\ZM,,T%U<&S9,X1" M1ESS6BD-!?)U2M74#FH?E5R8V7IO9PBVIP 4.N+*UJ!4'/C+G_O(B_UO0?(5 MUN"W$R!B]XK$>NU&'+N%%,657"1$>:B'[*'<43=6^H4V3/[6O;EK^_XI=V9H M\[;0HH?Z4M HH*2K4-$XU]:MG?S!2^N.'90W8F):)0QGSU0VYBP><$F"]^4[ M9E"^B%EHA2P4O%=$/*IL;N+5G9(QI6[Z1&_.-D!"!*P &A+$_/19*' >%\@T M=9N)9/PXFEG1^C8S^5M-K7_!AP;!1J=4\G5+EE M"@]T::YL0X_AFR) <6A\4-\H!,90$:;SSH&N&WO O;>V^,;]8+:>H1 P:P &0 &5A,#(P.#8U.2TX:U]A;&QA M2YH=&WM/6MWVKJRW_D5NNR[ST[6"6";-TDX"PBD- DDD%?[)4O8 MP8 MVY7E /WU9R3;@,$D)(7T<=JU=QM;HYG1C&8T,Y*8TA4!8)FO5 60"J.U9&D?//\>%!S#I,UL'*G&<8 M(;FO=L[GX"P:?@Z:8A2;3M^B(\Q A1Q3-B$I"26W@"3A$#6$")Z3 ^OI13R% M1%H.\*PH)SQ2WMS#SDSB&ED2=T 3&J"'D@D *>FO19M+06L Z#J) <;V#+B/ MG9X ]!M"6.$=M0SB1$*+EA"X:KDFH]-HCOW&4 >'LE74\#($5#D_[\R@L&%@ MJK,I&Q**;>(R7762JC42/:2RJ]W0<9V3"4L(84] KY:$\^K]$ C5T8F@EU"7L M$+7PB)301)L;KI_*R>GE9 ??"_AX8=7KT"A/'2'F!+G07D0 M/M'#X8AWKT##%7]RZ:-*KS"T#G?/TJ;(85.#',?[,/]*2)9LAJ[U$4"TR!AU MK!$V#[P7!T"?ZGT^S37]*>BFZ8YMX&D)F99)>)L^*?$I2RC8@7C0-8V8W"CX M$T"UW!'@4;T)/V$=[C\J3KO/9TA"RB7 DI"N'<<;6&42_Y..(Q,&#;2(7@I- MA'A9S(2C5 CS]]#*+-**G"KQ\GRN1!%.+8Z9LP$ND%!8E(DCVKFC+3EB!05V MD%@62T/A1<'T:"(PE.3$T>)^,P,/<1QW])%M$.X5?#(AS!XIQW*I3PF A-I+ M_N#%0)<&[_NJ )*( 0^^$(B=4W=DR<8U[(0 M1P0[+B5EWPA+ !*@"II"^#FN:.2>/:_#[P]>P+R1P-QI+!,!"P?%K0B4]Q23 M'3.+SEM?/?9E]B)P+E \(:8UTLT7:+XHCV6B$6B#YL7A+XO1-[VYI7DF[_N\ MHQ3T+<=BL2/[M9[U$(TP'>AF"7%0*0ZQ@PV8%E> CFN0Q"4>B,5OT0U[/1/, MLD7O %6B9S%FC?QW8UUC0\Z)]'<\U+MG46#>ZUTUL/J(%.# L0Q=.T1^8X#) M:Y?G[7QX"4?_!JL2O(V7__67G),./3GX?R^,(!4:PE;$%!"TMX'N$'%C3V!# M'\ K%7P4H2"L7OFFU;RNGZ#N=>6ZWCU*]MFO8LJK1-4OZ]] MJ+1.ZZC6OKAH=KO-=NL]N+C#SA"2269!_Y-D+8D4*9LI[ISR^^BTT>YV_)O('R9XI]ZZ1IWZ9;MS_1[3^=*ECHM-AI@%'56> M*R,YC=H=)&?WM'UD]='UD/ F%Y(@G3BQ^D0=8A/<545EO%DNIC._@_AY^,/' MTR&V11G:"YX)AL6.. R1)X!$5#03;;\$Z4)YV59J2[9R*>*GNA=<11M-][-] M?CEN/7U3AJ\R&J^V<1S7)ZRD ?81P XU/)T"P\0,&Y4L11E5B+EX^:-K$J3D M#Q"G\GO;F:J5S6;ZZ;M>X!:K9J MR;6Z?!^5[M4G, XQ &Y/=,8XP@YR;*+R9$A#.LB9.0B<"Y@7W7^_6<9PSR#0 M9!@@#Y47BN-@+OS9QIH6/+^:C87@091\P/N(^8MA2" M!E%FSXLRD]EYG/E$*--5; 2#\T"C!CQC)JW\'0]/?A&L]O%(-Z:EET:T&-A* M/+*-<(#5D($T3; JVS>L+@,W4_-JCS5+6V,OP]O3T=7X0^/I\LM;W2$O#_,D MF!&;6D]\WJWX0V75H)[E%98'8N Q>-9G':/_(]-6U+FL+$@MGM445U0P2R/0 M_:*SHQ&:'0W=("#&'J'14R&3'ZA3IIU_K0_>[CK3JYJ>T^7U&3F1D4'.?_3Z M'7HMAO1ZC2=-O\BE"FMZ3LF/7<):TN!FU.J_76]/"GG!1R*+(XCL3Z O$YXZFBPC^J$=3Y1BLM?JB M3]M_;AX_MTIN"+[%L=6LT4AW^!XNXL:*/-W]0@-H=KJH/K(-:TJHIXWP9$0M M*[D?. MD:(J1HE*K*AM>@E) RR<:_*3CX]6@5;3Z4GV.^*5PEIY+?$0+U]4-DG?-UKA MMA>$_E /JT3I[A+F%C8^Z_;ZS/*J>F_?ZU<7-]IWN-CB6LV%.(#$0I&EPJ\= M8?H#XT4;F\)LU&UL(#(AJLOT)U[+@6B&.!M'95] M/[ZTN;=L5Y)O5]QE5RC!ZRU)N?^4KTK%:6U:>+,E*:&2]"+->#DCR6LL9W_% MDP=W^P E5(U=I@O<*[E$)I=;7T)_I[+K MO$+\K[\*BIP_= #.(#;G%9F"V0.>(1HN#_5C&,0/,A#&L=LI&AC"[G>W-C:& MEL40MFT#7"ZX@'=34<.B,#?\TC@5-4QXQ)[?!>7TD;?7!OZ11P,Q SO!#M0[ M%LBW2V*V#-2&!.(*-B1<\M2")887-'K6!/6(88WYZ'DCEQ$J),YB?1UT-4"Z M Y.6$="=QC?@>K!X2]K-OR4"YL08@Y@+ Y M#=KZD)Y:8]Z/%X]U7H-P2KL5Q*^3DT=&(3YJ*:ED=7.KL=^2J\_ZKOZ.Z@PF M "\2N:9?4'&B_3WY-LH^G@^JV?J;=Q-*/4B4"3;%R'[*7!Q, MXX$(;??[ZS(.N4#33X^5:J]5W(4-A7:^UO/V$]L2,)U0%[A^<3V2,UI"V>OM M;V99'NP?V_J9;4N*MJVFX[B$OFAA4]QC#>-;I\]>=TQ@0PO+/F-A*QS^5G:6 M)HG,GKJ9G?FP/X&=[8C&0MSKI8^$0@)J1QV?Y0XGYJ>3(*@_V>,N=W2W?+CE MFE].]8[]JD.D&MAQ7G?JX%TV6;8]:(KYW$#=Z:AG&7N;E_1_W2&W_-.H0LTD M<&M@O>.A#F_F)O[Z?1JP$!C8@%K@-[F56+2$_JK5ZO5&X[VW<)XYH.G[LZFL M],2<7Y,!]BO9ZROIDE6_H](?VF%?IALO\P45!-]EEOIX@&Q,T1,V7(+^7TKR M'3=D\VN6P],@,EE_$#]]Y3YIG]NMMO,ZL2X?+.;.(NI,L5*(FN:+ M?'&OXVCXZQK9>Q: +C!]) R=G]?6;A/_#O%4T]1XZ$E0;XI4L1, O1[!_1)Q MG#%^P@C?1UT[M%X!4MI6Q0T5^J6'I7 MEM)HCX\R?R@*EP&P+NX?V/S^ =^/\<)@I9=0?%RQ!5Q1]Z!F2'E(/.^W@#:Y M):GN5$E4'PS!].IKQ+ULB_70@8R@UZGH5//ZK/%TM[>.]GEPKS>4[\W<&'67 M$[>(HQJ1O/DY6VY]SO;S:VQN5OUG#(5O]RY974Q8G;ZR+S8$FR(&9#1@4Z8E M\AO7(0(*R/J[;_P3.[K(>;SO!'#%"%K&E!,?ZT":3Q@31@0ME#SI#O0#2\6F MRFNF6!7?HN';S_S[1AJFFN/MNVGKDJOT'MX/+'O1!),KT[(2GI:3ZQF[WL6W M-3M&5^GQ>"RKI/"Z.ZR;51/24L2D7.'LY2K"NR64O_2E_85+^9&7]A ME_:CI,ZY/03HKRZO %2P;J(Y5:%N/1Q@\4<;5%)LA*AI9P(V^RP4@5CBZ/T MOPNQ0I\2_)CH$3 GX-$6/"]2S$40Y%R\DN*B+G]>-:XQ4 B)FXR,4#X)V5&' M#%S#.]W0.$$GNJ,:%O_$1W)GIU<6^=CQ41Z?E/\2%B_"D4K)K&Y&9=F0N_.+ MS&TS%KK+?( J_C>\^%WVV4>\#E#35)-HCZ\D_(24(AWZ$8%XD@_W8;WD!5X- M85B4^$E("DLBAF40FR;0Y?4U6("_Y7 MHGP>,PKB7GM >Q7Q&);D 5^EE%L$F-;X>8VU+)[ MTW@E0Y68:MFS@S]A#4/(WG>IJ3M#+FT>[0_UGLY0L9B4>3PB@OJ:2RFOI/N? M#. FZ!]6^M^2^]PE%;E+:LSB.W&:G6\V\/1-"X3H_$Z^*5[FG\E8&-F?6O_: M#<67"\ ^\:W?(0C,MV4E7[K1&XS_^VK96^;_A#@JU6UQN?--EP>B_ ,=]/84 M*7.@I L'2C:[/U?8%IGG#G/3BN(V908KI/B&(,&2(A5RV:(DDTFQF)!G'_1, M#ME(;(N"V^]X;O\ \2^I:&CI4RAX2P*_\QSR#H8K2YD?(.2:!0,7B06$4@PB M*U5<##G!#'OW=O?(J$I'F?XIFQ_O&/R"]4@Y1 M6]BK4^)8_?K%(;KE>QOOEWUM/L*HO;<-$O)X.?Q%5F_\AXA_L:N$*A3W=#7X M2"N74__.KJ MU LX8ZO5_ZB*_4%4X5-SC2E2L*F=QJ?O3$(5/B2<1Q7XL_VW6H< M]DPA81>7.K.J_NU5SJ#>\'KNFY//]5IZ;G ?N/L(YW;:OJ1 MQ7T?GDZ;\Q=%IO\UH]"]4&<31!W=N>_+(1\G#2^W$IGXR^5JV$]==6>3K(& M[9W>IVSKIG-*C=JYCO,U6FTQ1U&[7SNIL[O)\//D[E:_&]T53_5FXY,DV??3 M#U7KO'0]EF\OI@U9T=5;^]:JCS^V;R]/ M3NVT?ILMCF_JA>GM^;]S7_7V5+Z[ZIXV/T_.\\7JY/'B(U'H[2 U'#55UJU? M37,UM8MS6C8CI\YMZU;;7,;MQ'^SAG^!U1I-?:4;U(LQWJ))I(L M)VYDAQ653ONI ]Z!)*(C< ;N2,F_OL_BY7@B*<6Q:=7N-!^D"'?87>P^N]B7 M\]%/5V\NCIN-HY_.3U[B-Z/_CJY>7UV<'Q]U_6\\[8;'1Z>_O/P7&US]Z^+\ M^ZV15L4!V^GE!;N24V'96S%GEWK*5K6W=7QT>GQ^,Y%#6;#]_<[.4?<48O>7&'X*]6TU MM/GAINF^?O,C&UR>?;\E;O;WVSO_[O5V.K_EXRUV M?G/()H*4=<#VGNMS);)FH]"L;X3%=M;/N#HZO210OOKE[55=OK:5[X47 MT^-3;0NM&"T^^5NI!-O]KL5V>[O/GK+M:/+V9/#RY.\'<(F+RZM6W!QX+E$VZF/'$\><823XBE(L7?A"B )A4SD>F<() +8[6" M2M[C44)0@!Q&\&(*>T'F0J?\EG&E=(EG*3 WX05#?#$B$7*&34J#DV CHZ?N M!%Y0-BAT<',MBNK0_ED\%8NTYMRR<0 \AV-[R \]Y'D$?7 %&]'_I*8O MMQ3I=C;H_Q&-RP37(.D3XO;51%I6YC 6'3PHH,5TDI3&Z4(JQO/$3PD1HG2:5-,FUA*TBU@'%X]Y4VTV;C1?MG-I(0BXKAL;V^O]X0_?;)+_I!9 MS:Z5GD-1UO$[E6F[;P#-9H/>[C"G9$,;C7A72JC% Y!')ZD$L Z[4VBHX*1Y M!K/(:3EE0YE"GP1WR/WGG4ZO1P[$+'Q..+V"7":X+=BW/5!55B3PPYE@P])* M):QM-N!.]NL#Z(DE',VD+BW ]S "\&(FH3%N;AE!]A;Z!&@IH "@'P***G[" M $*E/F@!_P(!C7:E E<)-M!K(JPA'?$4/@_ M%"N4+>'VQ41[Q1(SY^1?M^;HCG# D=:6N'X5+J84_DLNXNYW'XDK"%78@<:M MUB[^PJ^@=.5"G]\-:]!=/N,RXT-$XT=0T6H#4>"P.\3XN/J1.('O(?LDIA-D#HCL0B8MG[79H;AR]?/V/*$@=H3N[:R#Z MG-:&VJ3"5&NGB(;7;*>S!YFLSF0*N=8&J>@'?_2XO^,Q=&"V0^G8+NGCJ(L# MK3G;$,'YNNTKB@.6.RW5Z3]?0Y]T4#]-3?UU:]YA63-%UXGF-/V%XF<#;9=' MCKT?U\ Y&>JR6%^4/VZWZ#,E?.NZ#'?:!50D\N5&P5#JN[V"9N/3F@5482W2 M"$EY=E):GUL'(O0>^:I%=JHI%QM2)T-I/&3]D\M^]XJKZUO#+8HVJ5PC$^F9 M*ZS2&?$#L1FV(2D)[',D:+Y30176V%6Y+R_[1X-?^\?;J')A"?K?4.)1[$LE M'RO<8#)QA ,!9D46@J/T>8Y68PV*S4:^U&C!D27/6NSMV57OVQ??O7CQ;+]3 M*UDLI4;INY)R3N-+)")'5UZ+A=R22G)ND@D;\02IJ*MTV$NA8.%K7\^ #$0. MQ0E5/VF*3=8)9 $@5X]#[%)-1<&FSF 94TCT+=%:-DZ'ZG(VI7Z*5*[^\:73 M3%KJORS=>E]T=@8?>^4:%0N=PV@#G< H[ T4P3?LU!L_P854UR)]C85)4>3V MH-LE V1N52HR0#=X8C=:I;CI;E" ?RXX%W."F'%,%\R^9.TY^YLY-VG[0NMK MG+ MUA!KIH*[WAXB+?W9-W)&!1RROQ+VE9#W K_&OK:]I*1HRDX2%YEW]O?W7+"X MAQV5>S.9BK4-%^I6NBZ/N,D13!U]RWP$%PFWV X6H[*@NADW0G5IS)%45F>E MNC&1.16-K=@=#X^&(I/8M[Q,VI*J7+->9FFKTE!8%5 [=5&7W_9"+Z^&3LKR M\I3?KBQ18K2\2-7TRII&($<1O")9KL&KH,ME>8>A %^L2 %C_+9&9CNI'SRN MSFDQKM$=8^44U;AA.+B[6V"L9@,'8["O(FBR^V'78D/D5 0"/K14:P2PV6C, M5 O7.'9@C(W6:C_=;_1PB8%#@Q7+R[CR%@"4*LG*5'@!J*E =*CAZ&_*EA/* M2'N-G,=:NA:*V'&,'=VEOG>MZ;6 @\?^E2@UK.'QLJ$=HS*[.'F/20BDVH0-N'T2*"$<;I>TZ2- M#6ED+NHA._OT924^D=Z'/"1W"'M(*.GU2!ZII \%[&XD6')^AT(B9I'(V@!G)R2M6H MT^LXI3,DL#0]"<,JC=U6.!0" 3@IE"M)HSC7\)9T/WE -1&L]PFZ#JC-QF,C ME:T':K/Q!Y!:&.ILCA>CCQ4XN0F(,S!EK=0Q#2.46S84;*8S( !KSJQMR+^ M:C9BP4#ODBL/*:1DKL-JN"0+E2,DNRY)3W@N"\K -5;S'&9S"7\$FS-R=7ND M2QF[76:/(P,+ 3=.(8LB"0;(N( MW'&W5/#JF7M6&B?&&AOXLI.[@6'I,@QWGMHEM1(V/:;]*XC%<'$J(S'&45*5 ?A2*I1/$U8SM?!?'GTX!@0**C/;/ M]/V%O^)]I[?A,"RAEU$)S:[WXM,3@_B]]*M!8A@@7\N*57%G+@ A_%[8U\.NNFZW$U5'R*[!DR]M7%/WD*-L!A":19?5$$ZO+$R38;L*BSK94F>?GKF"71F1\OKF&RKT?53W:5VK??//-QCCXGU)M'4=MGY%W M)L7!AEET=O>("X(6JC^-;"'S*>D/GV78$Q0G%=51!Q7W3^\FU.V1B5%Q_Y#$ M^"Y];_W4Q+7)'M#U?1K\(]WJ95FISX'W+.LC/T :KAZ+[1DW1A?RO6#]2[;- MI_FA"XRE"E\TV<<2Y*_/]MCSWO-=MO_M?N^QF!8V_R&)&M@HRN^(N,IXP[VS M3^+V 3/[#Y@VKH^'_Y_9_Z_.[!\)X!^!.3=:WJVFWH]QVG5?&]!WE>TXYK[O M4X)[#Q;GRKW>7[;N[*Y_@UW[Y,!16_.]0;0#C>'#S_H8_HZ0_P5<=.D?B?A_ M-4+_N.0_4$L! A0#% @ I$7<6.>Q83(R P !PP !$ M ( ! &%L;'(M,C R-# V,C'-D4$L! A0#% @ I$7<6%>%7>S^ M"@ @(8 !4 ( !80, &%L;'(M,C R-# V,C=?;&%B+GAM M;%!+ 0(4 Q0 ( *1%W%B V-XR7P< .U7 5 " 9(. M !A;&QR+3(P,C0P-C(W7W!R92YX;6Q02P$"% ,4 " "D1=Q8,>8+:>H1 M P:P &0 @ $D%@ 96$P,C X-C4Y+3AK7V%L;&%R:71Y M+FAT;5!+ 0(4 Q0 ( *1%W%CO]#O"FPP &,R > " M 44H !E83 R,#@V-3DP,65X.3DM,5]A;&QA2YH=&U02P4& 4 ,!0!8 0 '#4 end XML 18 ea0208659-8k_allarity_htm.xml IDEA: XBRL DOCUMENT 0001860657 2024-06-27 2024-06-27 iso4217:USD shares iso4217:USD shares false 0001860657 8-K 2024-06-27 ALLARITY THERAPEUTICS, INC. DE 001-41160 87-2147982 24 School Street 2nd Floor Boston MA 02108 401 426-4664 false false false false Common Stock, par value $0.0001 per share ALLR NASDAQ true false